IRLAB Therapeutics AB (publ) (IRLAB-A) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.00x

IRLAB Therapeutics AB (publ) (IRLAB-A) has a Cash Flow Reinvestment Rate of 0.00x as of September 2025, reinvesting Skr0.00 (capex Skr0.00 ) from operating cash flow of Skr5.26 Million. Check IRLAB Therapeutics AB (publ) (IRLAB-A) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.00x

(Capex + Investments) / Operating CF

Total Reinvested

Skr0.00

Capex + Investments

Operating Cash Flow

Skr5.26 Million

SEK

Capital Expenditures

Skr0.00

SEK

IRLAB Therapeutics AB (publ) Cash Flow Reinvestment Rate (2021–2021)

Historical reinvestment intensity for IRLAB Therapeutics AB (publ) across 1 annual periods. Explore IRLAB Therapeutics AB (publ) (IRLAB-A) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for IRLAB Therapeutics AB (publ) (2021–2021)

Year-by-year capital reinvestment analysis for IRLAB Therapeutics AB (publ). For live market cap and broader valuation context, see IRLAB-A stock market capitalisation.

Year	Reinvestment Rate	Total Reinvested (SEK)	Operating CF	Capex	YoY Change
2021	0.01x	Skr1.42 Million	Skr128.64 Million	Skr708.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow